Health Condition 1: null- Newly detected untreated cases of Hansens Disease Health Condition 2: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
None listed
Sponsors
IADVL Research Grants
Eligibility
Inclusion criteria
Inclusion criteria: All newly diagnosed untreated Hansenâ??s disease patients coming to the dermatology out-patient department of our hospital dyring the study period
Exclusion criteria
Exclusion criteria: i) Hansenâ??s disease patients on treatment or those who have completed treatment ii) Doubtful cases not confirmed by biopsy or SSS iii) Cases of pure neuritic Hansenâ??s disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| strength of expression of 16S RNA and 18 kDa antigen genes Morphological indexTimepoint: Baseline at 6 and 12 months of multidrug therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the change in RT-PCR expression of 16S RNA and 18-kDa genes in skin biopsy specimens at 6 and 12 months of chemotherapy. 2. To compare the percentage change in RT-PCR values of 16S RNA and 18-kDa genes with percentage reduction in Morphological index at 6 and 12 months post treatment in smear positive patients Timepoint: Baseline at 6 and at 12 months of therapy | — |
Countries
India
Contacts
Public ContactRanugha PSS
JSS Medical College and Hospital
Outcome results
None listed